1404PSafety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial. (23rd October 2018) - Morelli, A M; Migliorino, M R; Morabito, A; Chiari, R; Grossi, F; Bordi, P; Di Costanzo, F; Delmonte, A; Romano, G; Misino, A; Scotti, V; Gregorc, V; et al.